LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial
Authors:
- E. MayerEME. Mayer
- S. TolaneySTS. Tolaney
- M. MartinMMM. Martin
- G. VidalGVG. Vidal
- L. MoscettiLML. Moscetti
- K. JhaveriKJK. Jhaveri
- A. BrufskyABA. Brufsky
- W. GradisharWGW. Gradishar
- A. SchneeweissASA. Schneeweiss
- N. NiikuraNNN. Niikura
- A. FavretAFA. Favret
- M. AlfieMAM. Alfie
Top Cited Papers
- 20 November 2025
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 36, S1561-S1562